A company of Manulife Investment Management, John Hancock Investment Management serves investors through a unique multimanager approach, complementing our extensive in-house capabilities with an unrivaled network of specialized asset managers, backed by some of the most rigorous investment oversight in the industry. The result is a diverse lineup of time-tested investments from a premier asset manager with a heritage of financial stewardship. Note: This account is not managed or monitored by John Hancock Investment Management, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use John Hancock Investment Management’s official channels.

This article was written by

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given that any particular security, portfolio, transaction or investment strategy is suitable for any specific person. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security or other matter. You alone are solely responsible for determining whether any investment, security or strategy, or any product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. The author is an employee of Seeking Alpha. Any views or opinions expressed herein may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Shares of Wockhardt soared as much as 19% to their day’s high of Rs 2,420 on the BSE on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.

According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.

The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year.

The company also noted that complicated urinary tract infections account for more than 6,00,000 hospitalisations annually in the U.S., with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria.

The FDA’s decision was based in part on results from the Phase 3 ENHANCE-1 study, a randomised, double-blind, multicentre trial that evaluated the efficacy, safety and tolerability of ZAYNICH against meropenem in hospitalised adults with complicated urinary tract infections or acute pyelonephritis.

Also read: FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics market
In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem. The treatment difference was 20.6% with a 95% confidence interval of 12.3 to 29.5. The company said the drug was generally well tolerated during the trial.The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India.

Wockhardt stated that ZAYNICH targets penicillin-binding proteins PBP 1a/b, 2 and 3 simultaneously, a mechanism that it says provides bactericidal activity against multidrug-resistant Gram-negative bacteria for which treatment options remain limited.

The company also disclosed that ZAYNICH received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. In addition, Wockhardt has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the antibiotic.

Sensex, Nifty today: Catch all the LIVE stock market action here
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Shares of renewable energy player Suzlon Energy fall 2.2% to Rs 55.87 on the BSE on Monday after capital markets regulator Sebi levied penalties totalling nearly Rs 29 crore on Suzlon Energy and several former executives. Sebi concluded that the company misrepresented its financial position through transactions involving subsidiaries, inflated profits and inadequate disclosures.

In a 96-page order issued on May 29, Sebi said Suzlon and certain former executives violated provisions of the Sebi Act, PFUTP Regulations, listing regulations and disclosure requirements. The order replaces an earlier adjudication order issued in June 2025 and confirms multiple violations by the company and its executives.

Among the penalised individuals, former executive Vinod R. Tanti was fined Rs 5.75 crore, while Girish R. Tanti was directed to pay Rs 5.45 crore. Former Group CFO Kirti J. Vagadia was fined Rs 1.5 crore and former CFO Amit Agarwal was fined Rs 30 lakh.

The matter stemmed from an anonymous complaint received by Sebi in December 2019 alleging irregularities in transactions involving Suzlon’s subsidiaries and associate entities. A subsequent forensic audit and investigation covering FY15 to FY20 and the first nine months of FY21 examined several issues, including dealings with subsidiaries, impairment reversals, contingent liabilities and financial statement disclosures.

Sensex, Nifty today: Catch all the LIVE stock market action here

One key observation related to the transfer of Suzlon’s operations and maintenance services business to its subsidiary, Suzlon Global Services Ltd, in March 2014. Sebi noted that the business, valued at around Rs 77 crore, was transferred for Rs 2,000 crore, resulting in Suzlon recording an accounting gain of Rs 1,922.92 crore.
According to the regulator, the subsidiary lacked the financial capacity to fund the transaction. Sebi found that a significant portion of the consideration was subsequently reflected as paid through circular movement of funds between the two entities. The regulator said the arrangement created artificial profits and inflated the company’s net worth. It observed that Suzlon’s FY14 net worth would have been Rs 741 crore without the transaction, compared with the reported figure of Rs 2,664 crore.
Sebi further noted that Suzlon later booked an additional gain of Rs 829.78 crore by transferring its stake in the subsidiary to another wholly owned entity, effectively recognising profit a second time on the same underlying assets. According to the regulator, these transactions helped the company portray a stronger financial position and supported subsequent fund-raising and restructuring efforts.
The order also addressed a standby letter of credit connected to loans taken by a foreign subsidiary. Sebi said a contingent liability of about $569 million, or roughly Rs 4,050 crore, which had been disclosed in FY17, was not reflected in FY18 contingent liability disclosures after being reclassified under an accounting standard related to insurance contracts. The regulator held that the treatment was inappropriate and materially reduced the visibility of the company’s financial exposure.

In addition, Sebi reviewed investments and loans involving subsidiaries SE Forge Ltd and Suzlon Gujarat Wind Park. It found that several transactions involved circular routing of funds, conversion of loans into equity and later impairment of investments. According to the regulator, these transactions resulted in financial statements that did not accurately represent the underlying economic substance.

Sebi concluded that the company’s financial statements and disclosures failed to present a true and fair view of its financial position. The regulator said financial statements and disclosures form the basis on which investors and other market participants assess a listed company’s financial health and prospects.

While Sebi noted that disproportionate gains and investor losses could not be quantified with precision, it said the violations were serious because they related to financial information disseminated to investors and relied upon by the market.

Sebi imposed the penalties under provisions relating to fraudulent and unfair trade practices, disclosure lapses and violations of listing obligations. The notices must pay the penalties within 45 days of receiving the order.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Janus Henderson Investors exists to help clients achieve their long-term financial goals. Formed in 2017 from the merger between Janus Capital Group and Henderson Global Investors, we are committed to adding value through active management. For us, active is more than our investment approach – it is the way we translate ideas into action, how we communicate our views and the partnerships we build in order to create the best outcomes for clients. While our investment managers have the flexibility to follow approaches best suited to their areas of expertise, overall our people come together as a team. This is reflected in our Knowledge. Shared ethos, which informs the dialogue across the business and drives our commitment to empowering clients to make better investment and business decisions.www.janushenderson.com

Operator

Hello, and welcome to the Cango Inc. First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Mr. Paul Yu, Chief Executive Officer. Please go ahead.

Peng Yu
CEO & Director

Good morning, everyone, and thank you for joining Cango’s First Quarter 2026 Earnings Call. First, I will summarize our key financials and operational performance for the quarter. The first quarter of 2026 was characterized by industry-wide adjustments and our results reflect these macro headwinds alongside our ongoing efforts to manage our strategic transition. During Q1, we generated total revenue of approximately $102 million, primarily driven by revenue from our Bitcoin mining business. We reported a net loss from continuing operations of $261.1 million primarily due to noncash impairment charges on Bitcoin mining machines and loss from changes in fair value of receivable for Bitcoin collateral, both resulting from the decline in Bitcoin market price. By the end of the quarter, we held 1,025.7 Bitcoin, and we reduced our long-term debt to $30.6 million. As of March 31, 2026, Cango’s total operational hash rate was 37.01 exahash per second, comprising 27.98 exahash per second of self-mining capacity and 9.02 exahash per second of hosted hash rate. This operational model prioritizes margin resilience over scale.

In Q1, we mined 1,266 Bitcoin. Through disciplined cost management, our average cash cost per Bitcoin mined was $76,928 showing a 9% decrease from Q4 2025. These figures reflect our continued focus on profitability and operational efficiency as our business model evolves.